Semaglutide denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Semaglutide as Experimental

An experimental or investigational denial from Cigna typically means the plan's medical policy team has determined that the evidence base for semaglutide in your specific indication does not yet meet the plan's internal standard for "established" or "proven" therapy. This denial is most likely to appear when semaglutide is prescribed for an indication that is not yet listed as covered in Cigna's published medical policy for this drug — for example, an off-label use or a recently approved indication that Cigna's policy has not yet incorporated.

## Why This Denial Is Appealable

Semaglutide holds multiple FDA approvals. If your prescribed use falls within an FDA-approved indication, the experimental label is factually incorrect and directly contradicted by the regulatory record. Even for uses not yet in Cigna's policy, many plans are required under state law or plan terms to cover FDA-approved drugs for FDA-approved indications regardless of their own policy language. An appeal that documents the FDA approval status and relevant professional society support can be highly effective.

## Your Federal Appeal Rights

• Internal appeal: File a written internal appeal with Cigna citing the specific FDA approval for your indication. Under ERISA §503 or applicable state law, Cigna must provide a full-and-fair review with a reasoned written response.
• External review: Under ACA §2719, an independent review organization (IRO) can override an experimental denial if the IRO finds the service is not genuinely experimental. The external-review window is generally approximately four months from the final internal denial; verify the exact deadline on your denial notice.
• Expedited track: Available if delay would seriously jeopardize your health.

## Documentation to Gather

1. FDA prescribing label: Obtain the current FDA-approved prescribing information for semaglutide and highlight the specific indication that applies to your diagnosis. 2. Diagnosis confirmation: Comprehensive chart documentation of your confirmed diagnosis, including date of diagnosis, diagnostic criteria met, and relevant clinical findings. 3. Professional society guidance: A reference to the applicable clinical guideline organization (such as the American Diabetes Association, the Obesity Society, or the relevant cardiovascular society) that includes semaglutide as a recognized treatment option for your indication — without citing specific numeric thresholds. 4. Prescriber medical-necessity letter: A detailed letter from your physician or specialist explaining the clinical basis for the prescription, referencing the FDA-approved indication and professional guideline support. 5. Cigna's policy language: Obtain Cigna's current medical policy for semaglutide and identify exactly which criteria they use to classify a treatment as experimental, then address each criterion directly.

## Criteria-Mapping Structure

Review Cigna's published medical policy and identify every condition under which a treatment is deemed experimental. Then rebut each criterion with documented evidence:

| Cigna Experimental Criterion (from policy) | Your Rebuttal Evidence | |--------------------------------------------|------------------------| | Is the use FDA-approved for this indication? | [FDA approval date and indication text from the label] | | Is the use recognized in applicable professional society guidelines? | [Guideline organization name and publication date, no numeric thresholds] | | Is there peer-reviewed evidence supporting clinical benefit? | [Prescriber letter referencing the evidence base, no specific trial names or statistics] |

A well-structured rebuttal that maps your situation to each criterion gives the IRO a clear path to reverse the denial.